RedHill Biopharma (RDHL) Assets Average (2013 - 2025)

RedHill Biopharma (RDHL) has 13 years of Assets Average data on file, last reported at $21.9 million in Q4 2025.

• Assets Average for Q4 2025 came in at $21.9 million, up 9.12% year-over-year; the trailing twelve-month figure through Dec 2025 was $21.9 million (up 9.12% YoY), and the FY2025 annual result was $21.7 million, up 5.59% from the prior year.
• Assets Average rose to $21.9 million in Q4 2025 per RDHL's latest filing, from $18.2 million in the prior quarter.
• Over five years, Assets Average peaked at $211.9 million in Q2 2021 and troughed at $18.2 million in Q2 2025.
• A 5-year average of $114.7 million and a median of $158.0 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2021 and 2023: Assets Average surged 84.01% in 2021, then sank 81.62% in 2023.
• A 5-year view of Assets Average shows it stood at $183.8 million in 2021, then dropped by 14.0% to $158.0 million in 2022, then slumped by 81.62% to $29.0 million in 2023, then slumped by 31.02% to $20.0 million in 2024, then advanced by 9.12% to $21.9 million in 2025.
• Business Quant data shows RDHL's Assets Average at $21.9 million in Q4 2025, $18.2 million in Q2 2025, and $20.0 million in Q4 2024.